HRTS241220P41000
- 0.00
- 0.000.00%
Tema GLP-1, Obesity & Cardiometabolic ETF Newsroom
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Temporarily drops below the key level of 38,000 yen due to caution over Trump tariffs.
The Nikkei Average continued to decline. It closed the trading at 38,134.97 yen, down 307.03 yen (trading volume estimated at 1.82 billion shares). Today, due to concerns about the future of the global economy against the backdrop of the Trump administration's strengthened tariffs, selling pressure for risk aversion persisted. Additionally, the yen's appreciation, temporarily reaching the 152 yen to the dollar range, also had a negative impact on export-related stocks. As a result, the Nikkei Average widened its decline towards the end of the afternoon session, reaching 37,988.99 yen, breaking below the psychological milestone of the 38,000 yen level.
Active and newly listed stocks during the morning session.
*Dai Do Group HD <2590> 3240 +326 The cumulative operating profit for the third quarter has turned into an increase. *Janome <6445> 1187 +82 The stock remains strong, and buybacks are becoming more active. *Keisei Electric Railway <9009> 4662 +243 Viewed the sale of OLC shareholding as a catalyst. *Resonac <4004> 4170 +178 Interest as related to perovskite solar cells. *Oriental Land Co., Ltd. Unsponsored ADR <4661> 3585 +150 Responding to the sale of shareholding in Keisei Electric Railway.
Futu Morning Report | The US stock market party continues! The s&p 500 index has risen for seven consecutive days, setting a new historical high; Federal Reserve meeting minutes: future interest rate cuts will be cautious, and the end of monetary easing i
Market response to Trump's tariff threats: auto stocks wail, the Canadian dollar hits a four-year low, and the Mexican peso plunges nearly 3%; dell technologies drops over 10% after hours, with total net revenue for the third quarter at 24.37 billion USD, below analyst expectations.
Tradepulse Power Inflow Alert: Eli Lilly & Company Climbs Over 22 Points After Alert
Amgen weight loss drugs have a remarkable effect of reducing 20% body weight, but with relatively high side effects, leading to a temporary large drop of over 12% during trading hours.
Although the weight loss effect of amgen's MariTide drug met expectations, the high side effects, lower than eli lilly and co's Zepbound, and the trial results falling below Wall Street's high expectations, led to amgen's stock price plunging over 12.3% on Tuesday, far behind eli lilly and co and novo-nordisk a/s, which benefited from the Biden policy rise at the same time. In a one-year trial, MariTide helped non-diabetic patients lose up to 20% of their weight, comparable to the maximum dose effect of eli lilly's Zepbound. However, the side effects are significant, with about 11% of patients dropping out of the trial due to side effects, higher than eli lilly's 7%.
US stocks closed | The three major indices rose together, with Dow Jones and S&P hitting new highs; tariff threats dragged down auto stocks, general motors fell 9%
Waiting for PCE inflation, the Fed's November minutes support gradual rate cuts, temporarily suppressing US bond yields and the dollar while gold rallies. The Dow turns higher at the end of the day, hitting new highs for three consecutive days, while small cap stocks fall from the highest level in six days, with chip stocks down more than 1%, but nvidia rebounds by 0.7%. Tesla reverses its decline, Nio falls by 7.7%, Amgen's weight loss drug once fell by more than 12%, and Dell falls more than 9% after hours.
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Stocks Mixed Ahead Of Fed Minutes, Mexican Peso Tumbles To Over 2-Year Lows On Tariffs Fears: What's Driving Markets Tuesday?
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
Amgen Decline on MariTide Data Could Be Due to Lack of More Details
The Biden administration has proposed covering weight loss medications under Medicare, while Trump's team may become the biggest obstacle.
①The Biden administration has proposed expanding the coverage of federal medical care and medical subsidies to include weight loss drugs; ②The White House claims that these drugs can prevent type 2 diabetes, lower the risk of cardiovascular diseases such as heart disease, but currently they are too expensive for Americans. ③This proposal may be blocked by the Trump administration taking office next year, as Senator Kennedy opposes weight loss drugs.
Eli Lilly Stock Is Rising Tuesday: What's Going On?
4 Stocks to Watch on Tuesday: AMGN, BBY and More
Anavex Gains After Seeking EU Marketing Nod for Alzheimer's Drug
Amgen Reveals Data From Closely Watched Monthly Obesity Drug, With Weight Loss Of Up To 20% At One Year And No Plateau
FOMC meeting minutes incoming, US stock index futures show mixed movements | Highlights tonight
1. Intel has locked in $7.9 billion in US chip subsidies for advanced chip factories; 2. Rivian has secured a $6.6 billion conditional loan commitment from the US Department of Energy, planning to build in the US; 3. The Federal Reserve will release the minutes of the November meeting at 3 am Beijing time on Wednesday.
Amgen's weight loss drug can reduce weight by 20% in one year, but Wall Street is still not satisfied, causing a sharp drop in stock prices.
① The experimental obesity treatment drug MariTide from the usa pharmaceutical company amgen can help obese patients lose an average of up to 20% of their weight after one year of use, but the stock price plummeted due to data falling short of Wall Street expectations. ② Amgen claims that MariTide can lead to faster weight loss, maintain weight, and require fewer injections, but analysts question its potential side effects on bone density.
Amgen Shares Are Trading Lower Following the Results of Its Phase 2 Study With MariTide in Obesity.
Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau